Anne‐Marie Stoppa

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · Blood · 2007 · 899 citations · Full text

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel et al. · Journal of Clinical Oncology · 2010 · 419 citations · Full text

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Jean‐Luc Harousseau, Michel Attal, Xavier Leleu et al. · PubMed · 2006 · 335 citations

Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

Philippe Moreau, Michel Attal, Denis Caillot et al. · Journal of Clinical Oncology · 2017 · 310 citations · Full text

Oncologic Imaging, Pet-mri, Prospective Trial +19